Amalgamated Bank lifted its stake in Danaher Corporation (NYSE:DHR) by 58.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 68,858 shares of the conglomerate’s stock after purchasing an additional 25,372 shares during the quarter. Amalgamated Bank’s holdings in Danaher Corporation were worth $5,811,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Peddock Capital Advisors LLC increased its holdings in shares of Danaher Corporation by 17.4% in the first quarter. Peddock Capital Advisors LLC now owns 1,224 shares of the conglomerate’s stock valued at $105,000 after purchasing an additional 181 shares during the last quarter. Proficio Capital Partners LLC increased its holdings in shares of Danaher Corporation by 92.3% in the first quarter. Proficio Capital Partners LLC now owns 1,246 shares of the conglomerate’s stock valued at $105,000 after purchasing an additional 598 shares during the last quarter. ClariVest Asset Management LLC acquired a new stake in shares of Danaher Corporation in the first quarter valued at approximately $157,000. Motco increased its holdings in shares of Danaher Corporation by 8.8% in the second quarter. Motco now owns 2,011 shares of the conglomerate’s stock valued at $170,000 after purchasing an additional 163 shares during the last quarter. Finally, Cornerstone Advisors Inc. increased its holdings in shares of Danaher Corporation by 62.0% in the second quarter. Cornerstone Advisors Inc. now owns 2,111 shares of the conglomerate’s stock valued at $178,000 after purchasing an additional 808 shares during the last quarter. 75.66% of the stock is owned by hedge funds and other institutional investors.
WARNING: “Amalgamated Bank Has $5.81 Million Holdings in Danaher Corporation (NYSE:DHR)” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2017/10/27/danaher-corporation-dhr-shares-bought-by-amalgamated-bank.html.
Several research firms have issued reports on DHR. Wells Fargo & Company reissued a “market perform” rating on shares of Danaher Corporation in a research note on Saturday, July 22nd. Cowen and Company reissued a “buy” rating and set a $90.00 target price on shares of Danaher Corporation in a research note on Wednesday, October 4th. Jefferies Group LLC reissued a “buy” rating and set a $95.00 target price on shares of Danaher Corporation in a research note on Friday, August 4th. BidaskClub lowered Danaher Corporation from a “hold” rating to a “sell” rating in a research report on Tuesday, July 25th. Finally, Morgan Stanley restated an “overweight” rating and set a $95.00 price target (up from $86.00) on shares of Danaher Corporation in a research report on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $93.31.
In related news, insider William King sold 43,688 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $82.86, for a total transaction of $3,619,987.68. Following the completion of the sale, the insider now directly owns 45,748 shares of the company’s stock, valued at $3,790,679.28. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Daniel L. Comas sold 88,184 shares of the business’s stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $91.02, for a total transaction of $8,026,507.68. Following the transaction, the chief financial officer now owns 227,816 shares of the company’s stock, valued at approximately $20,735,812.32. The disclosure for this sale can be found here. Over the last three months, insiders have sold 163,411 shares of company stock valued at $14,431,927. 12.20% of the stock is currently owned by insiders.
Shares of Danaher Corporation (DHR) opened at 91.46 on Friday. Danaher Corporation has a 1-year low of $76.27 and a 1-year high of $91.72. The firm has a 50-day moving average price of $87.12 and a 200-day moving average price of $84.38. The firm has a market capitalization of $63.54 billion, a PE ratio of 29.19 and a beta of 1.03.
Danaher Corporation (NYSE:DHR) last released its quarterly earnings results on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, beating the Zacks’ consensus estimate of $0.95 by $0.05. Danaher Corporation had a net margin of 13.36% and a return on equity of 11.29%. The firm had revenue of $4.53 billion for the quarter, compared to analyst estimates of $4.47 billion. During the same period in the previous year, the business earned $0.87 earnings per share. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. On average, analysts forecast that Danaher Corporation will post $3.99 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, September 29th will be paid a $0.14 dividend. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.61%. The ex-dividend date is Thursday, September 28th. Danaher Corporation’s dividend payout ratio is presently 16.52%.
About Danaher Corporation
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.